Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifosfamide in Recurrent Germ Cell Tumors
NCT01808534Phase 2Terminated
- Sponsor
- Indiana University School of Medicine
- Start
- Feb 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palifosfamide in germ cell tumor (GCT), sponsored by Indiana University School of Medicine. Primary endpoint: Overall Response Rate up to 2 years. Started Feb 2013; status: terminated.
02
Drugs
palifosfamide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01808534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808534.